Cerus Corporation Announces Third Quarter 2026 Financial Results
Business Wire•02/11/2026•16:05 ET
0
Key Highlights
- ➤Q3 product revenue $57.7 million, up 10% year over year
- ➤Positive topline Phase 3 RedeS results announced for INTERCEPT RBC system
- ➤Full-year 2026 product revenue guidance reaffirmed at $229 million-$231 million
- ➤Q3 IFC volumes grew approximately 80% year over year
- ➤Q3 adjusted EBITDA positive $5.7 million, versus $5.0 million prior year
Expert Statements
Vivek Jayaraman, President and chief executive officer of Cerus Corporation
“Our solid performance in Q3 builds upon a strong first half of 2026 and increases our confidence as we approach year-end. Continued growth from our IFC business, core platelet franchise and international INT 200 rollout strengthens our foundation as we work to establish INTERCEPT as the global standard of care. The positive topline results we announced today from the Phase 3 RedeS study mark an important milestone as we drive toward extending the benefits of pathogen reduction to red cell transfusions. I’m pleased with our progress and grateful to my colleagues who remain focused on delivering for our customers and the patients they serve.”
Cerus Corporation Announces Third Quarter 2026 Financial Results
Third quarter 2026 total revenue of $64.0 million; third quarter 2026 product revenue of $57.7 million, +10% Y/Y
Get started
Create a free account to read the full story.